QGEN News & Events

Qiagen (QGEN) announced at the 2026 BIO-IT World Conference & Expo in Boston that the Qiagen Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating Nvidia (NVDA) accelerated computing and the Nvidia BioNeMo platform to help researchers use AI more effectively in drug discovery. The integration is designed to help pharmaceutical and biotechnology researchers better understand disease biology, identify promising therapeutic targets and uncover biomarkers that can support faster and more effective development of new medicines. "QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation."

Reports Q1 revenue $492M, one estimate $499.2M. "QIAGEN made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies, QIAcuity and QIAGEN Digital Insights," said Thierry Bernard, Chief Executive Officer of QIAGEN. "QuantiFERON was affected by significant decline in immigration testing demand, but we view this as a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing. We are focused on executing against our updated 2026 targets and positioning QIAGEN for faster growth in the second half of 2026. Our profitability for the first quarter reflected disciplined execution in a challenging environment, as we managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements and measures to ensure reliable product supply," said Roland Sackers, Chief Financial Officer of QIAGEN. "We are focused on delivering solid profitable growth through efficiency gains combined with disciplined capital allocation and targeted investments that strengthen QIAGEN's long-term growth potential and create value for shareholders."